Blockade of CD300A enhances the ability of human NK cells to lyse hematologic malignancies.

ABSTRACT:

Objective

The human cluster of differentiation (CD)300A, a type-I transmembrane protein with immunoreceptor tyrosine-based inhibitory motifs, was investigated as a potential immune checkpoint for human natural killer (NK) cells targeting hematologic malignancies (HMs).

Methods

We implemented a stimulation system involving the CD300A ligand, phosphatidylserine (PS), exposed to the outer surface of malignant cells. Additionally, we utilized CD300A overexpression, a CD300A blocking system, and a xenotransplantation model to evaluate the impact of CD300A on NK cell efficacy against HMs in in vitro and in vivo settings. Furthermore, we explored the association between CD300A and HM progression in patients.

Results

Our findings indicated that PS hampers the fu

SUBMITTER: Li S 

PROVIDER: S-EPMC11033714 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature